TPIDB > Principal Investigator
Principal Investigator
National Taiwan University Hospital
(在職)
Digestive System Department
Division of General Internal Medicine
更新時間：2023-09-19
高嘉宏Kao, Jia-Horng
- Principal Investigator
- Clinical Trial Experience (year) 23 years 9 個月
Publication
53Publications
21
Su TH, Kao JH. The clinical manifestations and management of COVID-19-related liver injury. J Formos Med Assoc. 2020 Jun;119(6):1016-1018. doi: 10.1016/j.jfma.2020.04.020. Epub 2020 Apr 24. PMID: 32345544; PMCID: PMC7180368.
22
Huang CF, Hung CH, Cheng PN, Bair MJ, Huang YH, Kao JH, Hsu SJ, Lee PL, Chen JJ, Chien RN, Peng CY, Lin CY, Hsieh TY, Cheng CH, Dai CY, Huang JF, Chuang WL, Yu ML. An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions. J Infect Dis. 2019 Jul 19;220(4):557-566. doi: 10.1093/infdis/jiz154. PMID: 30957170.
23
Tseng TC, Peng CY, Hsu YC, Su TH, Wang CC, Liu CJ, Yang HC, Yang WT, Lin CH, Yu ML, Lai HC, Tanaka Y, Nguyen MH, Liu CH, Chen PJ, Chen DS, Kao JH. Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy. Liver Cancer. 2020 Apr;9(2):207-220. doi: 10.1159/000504650. Epub 2020 Jan 10. PMID: 32399434; PMCID: PMC7206589.
24
Hsu SJ, Enkhzaya S, Lin YY, Tseng TC, Khosbayar T, Tsai CH, Wang TS, Enkhtuya D, Ivshinkhorol D, Naranzul N, Jargalsaikhan B, Amarsanaa J, Baatarkhuu O, Kao JH. Resistance-associated substitution and ledipasvir/sofosbuvir therapy in Mongolian chronic hepatitis C patients. J Formos Med Assoc. 2020 Mar;119(3):712-719. doi: 10.1016/j.jfma.2019.10.003. Epub 2019 Oct 28. PMID: 31672433.
25
Su TH, Peng CY, Tseng TC, Yang HC, Liu CJ, Liu CH, Chen PJ, Chen DS, Kao JH. Serum Mac-2-Binding Protein Glycosylation Isomer at Virological Remission Predicts Hepatocellular Carcinoma and Death in Chronic Hepatitis B-Related Cirrhosis. J Infect Dis. 2020 Feb 3;221(4):589-597. doi: 10.1093/infdis/jiz496. PMID: 31574141.
26
Liu CH, Liu CJ, Hung CC, Hsieh SM, Su TH, Sun HY, Tseng TC, Chen PJ, Chen DS, Kao JH. Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan. Liver Int. 2020 Apr;40(4):758-768. doi: 10.1111/liv.14295. Epub 2019 Nov 11. PMID: 31710759.
27
Hsiao CY, Teng X, Su TH, Lee PH, Kao JH, Huang KW. Improved quantitative assessment of HBV-associated liver fibrosis using second-harmonic generation microscopy with feature selection. Clin Res Hepatol Gastroenterol. 2020 Feb;44(1):12-20. doi: 10.1016/j.clinre.2019.04.003. Epub 2019 May 7. PMID: 31076362.
28
Chen CL, Kuo MJ, Yen AM, Yang WS, Kao JH, Chen PJ, Chen HH. Gender Difference in the Association Between Metabolic Factors and Hepatocellular Carcinoma. JNCI Cancer Spectr. 2020 May 8;4(5):pkaa036. doi: 10.1093/jncics/pkaa036. PMID: 33134821; PMCID: PMC7583157.
29
Ogawa E, Toyoda H, Iio E, Jun DW, Huang CF, Enomoto M, Hsu YC, Haga H, Iwane S, Wong G, Lee DH, Tada T, Liu CH, Chuang WL, Hayashi J, Cheung R, Yasuda S, Tseng CH, Takahashi H, Tran S, Yeo YH, Henry L, Barnett SD, Nomura H, Nakamuta M, Dai CY, Huang JF, Yang HI, Lee MH, Jun MJ, Kao JH, Eguchi Y, Ueno Y, Tamori A, Furusyo N, Yu ML, Tanaka Y, Nguyen MH; Real-World Evidence from the Asia Liver Consortium Investigators. Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice Implication. Clin Infect Dis. 2020 Dec 31;71(11):2840-2848. doi: 10.1093/cid/ciz1160. PMID: 31777940.
30
Tsai PC, Chen CY, Kuo HT, Hung CH, Tseng KC, Lai HC, Peng CY, Wang JH, Chen JJ, Lee PL, Chien RN, Yang CC, Lo GH, Kao JH, Liu CJ, Liu CH, Yan SL, Bair MJ, Lin CY, Su WW, Chu CH, Chen CJ, Tung SY, Tai CM, Lin CW, Lo CC, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Yeh ML, Huang CF, Hsieh MH, Huang JF, Dai CY, Chung WL, Ke CK, Yu ML. Successful Antiviral Therapy Reduces Risk of Schizophrenia Among Chronic Hepatitis C Patients: A Nationwide Real-World Taiwanese Cohort (T-COACH). Open Forum Infect Dis. 2020 Aug 31;7(10):ofaa397. doi: 10.1093/ofid/ofaa397. PMID: 33376753; PMCID: PMC7751132.
